cyrilzakka/clinical-trials huggingface dataset:
Can Entertaining Action-video Games Enhance Dynamic Visual Function and Improve Balance? A Randomized Controlled Trial.

This project is aimed to find out whether action video games can enhance dynamic visual function and improve balance function in the community-dwelling older adults. It is also aimed to examine the relationship between dynamic visions and balance functions.

Balance control is an important component even in a very simple daily task like walking. However, as we age, our physical and visual function would gradually deteriorate even in the absence of health or eye problems. Improving elderly balance control through different training is one way to prevent falls. In our project, we investigate the use of action video games, which is easy-to-find and entertaining, as a visual function trainer to improve balance of older adults.

We hypothesize that the training would show an improvement in both balance and dynamic vision. Our primary hypothesis is that postural sway in static and dynamic balance measures will improve after action video-game intervention. For secondary outcome measures, we hypothesize that the training will improve dynamic visual function (as measured by dynamic visual acuity and dynamic contrast sensitivity), and visual attention measures (as measured by useful field of view, multiple object tracking and spatial attention).

Eligibility Criteria:
Inclusion Criteria:

* Ability to understand and speak Cantonese
* No formal training or regular practice of balance function (e.g. Tai-chi)
* Little and preferably no video-game experience
* Best corrected distance acuity of 0.2 logMAR or better

Exclusion Criteria:

* Any diagnosed ocular diseases and ocular-motor abnormalities
* Suffering form severe medical problems or self reported neurological or cognitive disorders
* Suffering from physical impairments or physical limitations restricting them from training
* Having self reported vestibular or cerebellar dysfunction, history of vertigo or severe hearing loss
* Suffering from crippling arthritis, or a recent fracture of lower limb
* Planned major surgery during the trial
Measuring Lung Mechanics in Patients with COPD Using the REOM Handheld Portable Device

The purpose the study is to determine the agreement between the information obtained about lung mechanics (lung function) from the Rapid Expiratory Occlusion Monitor (REOM) handheld portable device with that obtained by conventional oscillometry as well as by pulmonary function testing (PFT), in patients with both 'mild' as well as 'very severe' forms of chronic obstructive pulmonary disease (COPD). This study also intends to study the user experience with this handheld portable device.

The primary objective of this cross-sectional study is to determine the concordance and agreement between the parameters obtained from the REOM, Reo1 and Reo2, and the conventional resistance parameters obtained by the tremoflo oscillometer device (R19 and R5, respectively) in adults with COPD confirmed by diagnostic pulmonary function testing (PFT).

The secondary objectives are:

1. To investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD.
2. To collect descriptive information on the participant user experience with the REOM.
3. To determine concordance between the parameters obtained from the REOM and those obtained from the tremoflo oscillometry device with the 'standard' parameters obtained from each participant's standard Pulmonary Function Tests (PFT).

Hypothesis:

We hypothesize in the adult COPD patient population that the REOM parameter Reo1 and tremoflo device parameter R19 will correlate closely, and that the REOM parameter Reo2 and tremoflo device parameter R5 will correlate closely. We also hypothesize that the REOM, in particular, Reo2, will be able to distinguish between 'mild' and 'very severe' COPD, and that participants will report a positive user experience with the REOM.

Eligibility Criteria:
Inclusion Criteria:

* Males and females aged ≥40 with COPD, former/current smokers with a ≥10 pack-year smoking history.
* Diagnosed with COPD by FEV1/FVC \< 0.7 using standard PFT post-bronchodilator testing, with either 'mild' ('GOLD 1': FEV1 ≥ 80% of predicted value) COPD or 'very severe' ('GOLD 4': FEV1 \< 30% of predicted value) COPD.
* Ability to provide informed consent.

Exclusion Criteria:

* No existing COPD diagnosis
* History of co-morbid asthma
* Current use of home oxygen
* Any acute exacerbation of COPD (AECOPD) experienced within 4 weeks of participation in the study
* Chronic respiratory infection
* Any contraindication to respiratory testing
* Inability to participate in reproducible measurements due to physical or cognitive barrier
Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism

Primary aldosteronism (PA) is thought to be the most common secondary endocrine form of hypertension. Compared with patients with essential hypertension with similar blood pressure, patients with PA have significantly higher atrial fibrillation, myocardial infarction, heart failure, stroke, deterioration of renal function and all-cause mortality. Therefore, early and systematic implementation of effective surgical or medical treatment is essential to prevent or reverse the excess vascular events and mortality of these patients. The patients with bilateral PA were mainly treated with mineralocorticoid receptor antagonists (MRAs). The MRA spironolactone is effective at lowering BP and reversing the harmful metabolic consequences, but its use is limited by adverse effects such as gynaecomastia, mastodynia, menstrual abnormalities and impotence due to its agonist activity at the progesterone receptor and antagonist activity at the androgen receptor. Finerenone is claimed to be a more selective blocker of the mineralocorticoid receptor than spironolactone being associated with fewer antiandrogenic side-effects. In this study, we will compare the efficacy, safety and tolerability of finerenone versus spironolactone in patients with hypertension associated with primary aldosteronism.


Eligibility Criteria:
Inclusion Criteria:

* 1.Age: 18-75 years old.
* 2.History of hypertension, DBP \<120 mmHg, SBP \<180 mmHg.
* 3.Serum potassium level ≥ 2.5 mmol/L.
* 4.Primary Aldosteronis diagnosed by increased aldosterone renin ratio (ARR) \> 30 ng/dl: ng/ml/h, and serum aldosterone levels ≥15 ng / dl, and confirmed by captopril inhibition test.

Exclusion Criteria:

* 1. Abnormal renal function: serum creatinine ≥ 2 × ULN or eGFR ≤ 60 ml/(min \* 1.73m2);
* 2. Abnormal liver function: ALT and AST ≤ 2.5 × ULN, TBIL ≤ 1.5 × ULN；
* 3. Cardiac insufficiency, acute myocardial infarction, stroke or other acute cardiovascular events within 6 months;
* 4. Take spironolactone, guanethidine or reserpine 30 days before enrollment;
* 5. Known or suspected tumor; Other autoimmune diseases, uncontrolled infectious diseases, serious respiratory, blood and nervous system diseases;
* 6. There is a pregnancy plan in pregnancy or 3 months before and after treatment. Breast-feeding women;
* 7. Those who have mental illness, alcohol or drug abuse and cannot cooperate with treatment.
A Study Comparing Vaginal Misoprostol and Intravenous Oxytocin for Induction of Labor

This study will compare the effectiveness of vaginal misoprostol (Cytotec) and intravenous oxytocin (Pitocin) in multiparous women who present at term for labor induction.

Both oxytocin and misoprostol have been demonstrated to be safe and effective methods for induction of labor. A direct comparison of efficacy and time to delivery in multiparas has not been specifically investigated. Additionally, the study will look at costs of the two drugs.Oxytocin is administered through an IV so requires more direct patient care time from the Registered Nurse, IV pump, and tubing, whereas misoprostol is a tablet, administered only once, per vagina or orally, every 4 hours. Misoprostol is also very inexpensive comparatively; if equally or more efficacious than oxytocin, this could demonstrate quite a cost and time savings to Vanderbilt University Medical Center and other institutions. Safety of either drug is not in question.

Eligibility Criteria:
Inclusion Criteria:

* Clinical candidate for labor induction utilizing either misoprostol or oxytocin
* Greater than or equal to 18 years of age
* Multiparous
* Singleton gestation;
* Greater than 37 weeks gestation;
* Cephalic presentation

Exclusion Criteria:

* Any clinical contraindication to misoprostol as induction drug
* Age less than 18 years
* Contraindication to vaginal birth
* Nonreassuring fetal heart rate tracing
* Prior uterine surgery
* Active labor
* Active maternal bleeding
* Chorioamnionitis (infection)
Simulation of Stent-graft Deployment in Aortic Arch Aneurysms

Total endovascular repair of the aortic arch represents a promising option for patients ineligible to open surgery. Custom-made design of stent-grafts (SG), such as the Terumo Aortic® RelayBranch device (DB), requires complex preoperative measures. Accurate SG deployment is required to avoid intraoperative or postoperative complications, which is extremely challenging in the aortic arch. In that context, the investigators aim is to develop a computational tool able to predict SG deployment in such highly complex situations. Four patient-specific cases will be performed with complete deployment of the DB and its bridging stents in aneurysmal aortic arch. Deviations of simulation predictions from actual stent positions will be estimated based on post-operative scan and a sensitivity analysis will be performed to assess the effects of material parameters. If good agreement between simulation and reality is obtained, numerical simulations will show their ability to successfully predict the DB deployment in complex anatomy. The results will emphasize the potential of computational simulations to assist practitioners in planning and performing complex and secure interventions.

The process of numerical simulation of double-branched device in aortic arch aneurysm involves: (i) aortic arch segmentation with data from the preoperative CT-scan (ii) numerical modeling of the actual stentgraft used to treat the patient (iii) simulation of stentgraft deployment in aortic arch (iv) validation of simulation results based on post-operative CT scan images The goal of this study is to develop a numerical model of stentgraft deployment able to predict the actual deployement of the double branched device in aortic arch aneurysm.

Eligibility Criteria:
Inclusion Criteria:

* Aortic arch aneurysms suitable for treatment using double-branched device Bolton

Exclusion Criteria:

* Failure to generate an adequate FE model of patient arteries (no preoperative multidetector contrast-enhanced CT-scan available, preoperative CT-scan slice thickness greater than 1mm, preoperative CT- scan with artifacts)
* dissected aneurysm
Exploring Oxytocin Response to Meditative Movement

This pilot study is designed to test effects of a single session of meditative movement (Tai Chi Easy) on older adults' blood pressure, perceptions of connection, mood, and oxytocin levels.

Endogenous oxytocin (the "cuddle hormone") is associated with lowering blood pressure (BP), suggesting that finding ways to increase oxytocin even in the absence of social connection, may be beneficial. Meditative movement emphasizing breath, meditative state and flow-inducing movements holds potential for reducing BP, improving mood and releasing oxytocin. In a single-group pilot study we exposed 21 OAs with mild-moderate hypertension to a 50-minute "Tai Chi Easy (TCE)" (simplified Tai Chi/Qigong) session, collecting BP, saliva samples for oxytocin, and psychosocial measures (connection, mood) pre/post intervention.

Eligibility Criteria:
Inclusion Criteria:

* Age 55-80 --BP above 120/80 -

Exclusion Criteria:

* having a neurologic disorder such as Parkinson's, seizure disorder, multiple sclerosis, Alzheimer's disease
* answered "yes" to one or more questions on the Physical Activity Readiness Questionnaire (PAR-Q). The PAR-Q is a seven-question assessment that determines one's readiness, safety and ability to engage in physical activity and is safely validated for older adults
Impact of a Letter Encouraging Pneumococcal Vaccination on the 1-year Vaccination Rate in Heart Failure Patients With a Primary Care Physician

Heart failure affects more than 1.5 million people in France, resulting in over 70,000 deaths and more than 165,000 hospitalizations each year. Viral and bacterial infections are frequently associated with episodes of acute heart failure in patients with chronic heart failure (CHF). Lower respiratory tract infections, such as influenza and pneumococcus, are common causes of hospitalization for decompensated heart failure, leading to increased morbidity and mortality. Studies have shown that pneumococcal vaccination can reduce the risks of heart attack or stroke in patients with heart failure. However, despite vaccination recommendations, coverage rates remain low, especially for pneumococcus. In this study, we will evaluate the impact of an incentive letter for pneumococcal vaccination on one-year hospitalization rate in patients with heart failure.


Eligibility Criteria:
Inclusion criteria:

* Adult patients over 45
* Residing in the Occitanie region, France
* With heart failure registered as ALD
* Who have declared an attending physician
* Who have not received a pneumococcal vaccination for more than 24 months (due to the length of time available in the database)

Exclusion criteria:

-None
Motor Control Exercises and Neural Mobilization in Posture of Older Adults

The aim of this research is to find and compare the effect of Motor control exercises with and without neural mobilization on postural control of older adults.

Randomized controlled trials done at Bilqees Eidhi and Afiyat old age home Lahore.The sample size was 40. The subjects were divided in two groups, 20 subjects in Motor control exercise group and 20 in Motor control exercise with neural gliding group. Study duration was of 6 months. Sampling technique applied was purposive non probability sampling technique. Only 65-80 years of older adults included in study. Tools used in the study are time up and go test(TUG), Gait speed, Static balance and Quality of life(OPQOL35). Data was analyzed through SPSS 21.

Eligibility Criteria:
Inclusion Criteria

* Both male and female were included
* Older adults having age range from 60-80 years or older
* Adults whose score is more than 24 on mini mental state examination.
* Ambulate independently with or without a walking aid
* Adults who had permission from the institution's doctor to participate in exercise classes.

Exclusion Criteria:

* Patients with altered conscious level
* Adults who cannot ambulate (bed ridden patients)
* Patient with any neurological condition like stroke, multiple sclerosis and TBI
* Patients with severe orthopedic condition like fractures and rheumatoid arthritis
* Patient having any cardiac condition
* Adults walking with walking aids like sick and crutches
* Adults having vertigo or vestibular problems.
* Adults having history of recurrent falls.
Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

The purpose of this study is to investigate the efficacy, safety, and pharmacokinetics of adalimumab following subcutaneous (SC) administration of 2 dosing regimens in Chinese subjects with Crohn's disease.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects of Chinese descent with full Chinese parentage.
2. Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0 confirmed by endoscopy, radiologic evaluation, and/or histology during the Screening Period.
3. Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450 despite treatment with oral corticosteroids and/or immunosuppressants.
4. Subject has a negative Tuberculosis (TB) Screening Assessment.

Exclusion Criteria:

1. Subject with ulcerative colitis or indeterminate colitis.
2. Subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.
3. Subject with an ostomy or ileoanal pouch.
4. Subject who has short bowel syndrome.
5. Subject with symptomatic known obstructive strictures.
6. Subject with an internal or external fistula (with the exception of an anal fistula without abscess).
7. Chronic recurring infections or active TB.
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.


Eligibility Criteria:
Inclusion Criteria:

1. A diagnosis of GPP or EP prior to the screening visit.
2. Candidate for phototherapy or systemic therapy.

Exclusion Criteria:

1. Other forms of psoriasis.
2. History of recent infection.
3. Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.

Other protocol defined inclusion/exclusion criteria apply.
Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease

This is an observational study, meaning participants will not receive any investigational treatment as part of this study.

Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.

Each participant of the study will have their data collected from the date of confirmed diagnosis of PD to the date of enrollment in the registry, post consent. Data will be collected from the participant's clinical records as well as from the participant directly. Data will be collected through Pulse Infoframe's technology platform.

Eligibility Criteria:
Key Inclusion Criteria:

* Any adult with a confirmed clinical diagnosis of PD.
* Age 18 years (or age of majority in their jurisdiction) or older at time of enrollment.
* Willing to participate in the registry (including completion of ePROs) and complete the informed consent form.
* Having received PD treatment within 2 weeks before enrollment, at enrollment or any time after the date of enrollment. After a confirmed diagnosis of PD, not having received PD treatment.
* Able to participate in English based registry.

Key Exclusion criteria:

* Not having a clinical diagnosis of PD.
* Age less than 18 years.
* Do not provide informed consent.
Novel BIochemical Markers for Predicting Type 2 NEurological Complications of Surgical Coronary Revascularization (BINER)

In this single center prospective cohort study a total of 100 patients scheduled for elective off-pump CABG will be recruited. They will be allocated to one study and one control group according to the presence or absence of postoperative type 2 neurological complications. The two groups will be compared in terms of serum concentrations of glial fibrillary acidic protein (GFAP), neuroserpin (NSP), phosphorylated axonal neurofilament subunit H (pNfH) and visinin-like protein 1 (VILIP-1) at the time of skin incision and closure as well as 24 hours and 7 days following surgery. Diagnostic performance of these markers for predicting type 2 neurological complications of off-pump CABG will be assessed.


Eligibility Criteria:
Inclusion Criteria:

* patients scheduled for elective off-pump Coronary Artery Bypass Grafting (CABG)

Exclusion Criteria:

* neurological or psychiatric disorders
* alcohol or drug abuse
* preoperative left ventricular ejection fraction of less than 30%
* extracranial carotid artery stenosis of more than 70%
* scoring below age- and education-adjusted cut-off values in Mini-Mental State Examination (MMSE)
* scoring over seven points on the subscales of the Hospital Anxiety and Depression Scale (HADS)
Study of Acupuncture on Postoperative Delirium in Patients With Diabetes Mellitus

1. To evaluate the effectiveness and safety of acupuncture on POD in diabetic patients undergoing surgery, to provide effective prevention and treatment measures of integrated traditional Chinese and western medicine for reducing the incidence of postoperative delirium in high-risk groups, and to provide clinical basis for further promotion of integrated traditional Chinese and western medicine anesthesia in the future.
2. To investigate the relationship between POD and rSO2 in diabetic patients undergoing surgery. To clarify the predictive value of intraoperative rSO2 monitoring on postoperative cognitive function in patients with diabetes, and to explore the effect of acupuncture on cerebral blood flow perfusion in patients with diabetes.

Postoperative delirium (POD) increases the risk of postoperative dementia and mortality. Cognitive decline is common in patients with diabetes mellitus. As an independent risk factor for POD, diabetes significantly increases postoperative dementia and mortality. Our team found that acupuncture can reduce the incidence of POD in elderly patients, increase regional cerebral oxygen saturation (rSO2), and increase cerebral blood flow perfusion in diabetic patients. In this study, a prospective randomized controlled study with placebo acupuncture will be conducted. Diabetic patients undergoing elective surgery will be divided into acupuncture group, placebo acupuncture group and control group. Acupuncture will be used as the intervention method, and the incidence of POD will be the main therapeutic effect evaluation index to explore the efficacy of acupuncture in the prevention and treatment of POD in diabetic patients undergoing surgery.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing general anesthesia in our hospital
* Expected duration of operation \>2h
* Ages 18-60
* With type 2 diabetes
* American Society of Anesthesiologists (ASA) grade 2-3 , no severe respiratory, circulation, liver, kidney, coagulation function abnormalities;
* Expected postoperative hospital stay \>3 days
* No history of cerebrovascular accident in the past six months
* The informed consent signed

Exclusion Criteria:

* Unable or unwilling to cooperate with cognitive function scale tests
* MMSE score \<24
* Refuse acupuncture treatment or have a history of needle sickness
* With skin damage at the acupuncture sites
* Coagulation dysfunction
* Participated in other clinical studies